Expand CTXR Menu
CTXR MENU

CTXR Latest Press Releases

-- September 3, 2026 --

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences PRNewswire 8:30 AM

-- August 14, 2026 --

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PRNewswire 4:30 PM
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PRNewswire 4:30 PM

-- August 12, 2026 --

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri PRNewswire 8:01 AM

-- August 5, 2026 --

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment PRNewswire 9:17 AM

-- July 21, 2026 --

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption PRNewswire 9:17 AM

-- June 1, 2026 --

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies PRNewswire 7:00 AM

-- May 26, 2026 --

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PRNewswire 8:00 AM

-- May 15, 2026 --

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update PRNewswire 4:30 PM
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update PRNewswire 4:30 PM

-- April 29, 2026 --

Citius Oncology Ships First International Order of LYMPHIR to Europe PRNewswire 8:00 AM

-- April 24, 2026 --

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules PRNewswire 4:30 PM
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules PRNewswire 8:00 AM
Market Data Delayed 15 Minutes